Adorf D, Grajer K H, Kaboth W, Nerl C
I. Medizinische Abteilung, Städtisches Krankenhaus München-Schwabing, Germany.
Clin Investig. 1994 May;72(5):390-2. doi: 10.1007/BF00252834.
A 26-year-old woman was admitted to hospital with high fever, severe tonsillitis, and gastroenteritis. Because of Graves' disease she had been treated with methimazole for 18 months. Leukopenia and agranulocytosis in combination with a typical bone marrow, exhibiting a complete arrest of myelopoiesis at the stage of promyelocytes led to the diagnosis of an antithyroid therapy induced agranulocytosis. After 1 week of antibiotic treatment without changes in neutrophil counts, granulocyte colony stimulating factor treatment at a dose of 300 micrograms/day subcutaneously was started. Twenty-four hours after the first administration the neutrophil counts began to rise, to 4389/microliters, with a maximum after the third administration and stabilizing at normal levels within 10 days. Since agranulocytosis is considered to be a severe and fatal complication of methimazole therapy, treatment with granulocyte colony stimulating factor seems to be useful for this life-threatening condition.
一名26岁女性因高热、严重扁桃体炎和肠胃炎入院。由于患有格雷夫斯病,她已接受甲巯咪唑治疗18个月。白细胞减少症和粒细胞缺乏症,结合典型的骨髓表现,即早幼粒细胞阶段骨髓造血完全停滞,导致诊断为抗甲状腺治疗引起的粒细胞缺乏症。在进行了1周抗生素治疗但中性粒细胞计数未改变后,开始皮下注射剂量为300微克/天的粒细胞集落刺激因子治疗。首次给药24小时后,中性粒细胞计数开始上升,至4389/微升,第三次给药后达到最高值,并在10天内稳定在正常水平。由于粒细胞缺乏症被认为是甲巯咪唑治疗的一种严重且致命的并发症,因此粒细胞集落刺激因子治疗似乎对这种危及生命的状况有用。